BRAF and neoplasm: More recently, re‐challenging non‐responding tumour after a drug holiday period has been suggested as an alternative therapeutic strategy in BRAF‐mutated melanomas8, 9 and it has been shown to be beneficial in a subset of patients.10, 11, 12, 13, 14, 15 However, safe longitudinal biomarkers to identify the patients who may benefit from the intermittent treatment, or to establish the optimal drug holiday duration, are missing.